Active Ingredient History

  • Now
Buparlisib is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. Buparlisib was under investigation as a treatment for advanced breast cancer but was abandoned due to negative results. It is still under investigation as a potential treatment for head and neck squamous cell carcinoma (HNSCC).   Wikipedia

  • SMILES: Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
  • Mol. Mass: 410.4
  • ALogP: 1.81
  • ChEMBL Molecule:
More Chemistry
bkm120 | bkm 120 | bkm-120 | bkm120-nx | bmk120 | buparlisib | nvp-bkm120


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue